MYCOF.US Mydecine Innovations Group Inc

Healthcare Pharmaceuticals USA Stocks
0.7300 USD
Close of Nov 15, 2026
0.1308 2.04
Market cap
USD 42.7M
P/E
0.4x
P/B
31.66x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is MYCOF.US undervalued?

Graham number
Price0.7300
Graham value0.9903
Discount26.3%

MYCOF.US trades 26.3% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mydecine Innovations Group Inc fundamental analysis

No fundamental analysis for Mydecine Innovations Group Inc yet.

Mydecine Innovations Group Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mydecine Innovations Group Inc

Noveris Health Sciences Inc., a biotechnology company, engages in developing and commercializing solutions for treating mental health problems and enhancing vitality. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. Noveris Health Sciences Inc. was formerly…

Full company profile